- Home
- NTLA vs PDM Comparison
NTLA vs PDM Comparison
Compare NTLA & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- PDM
- Stock Information
- Founded
- NTLA 2014
- PDM 1997
- Country
- NTLA United States
- PDM United States
- Employees
- NTLA N/A
- PDM N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PDM Building operators
- Sector
- NTLA Health Care
- PDM Real Estate
- Exchange
- NTLA Nasdaq
- PDM Nasdaq
- Market Cap
- NTLA 931.3M
- PDM 1.0B
- IPO Year
- NTLA 2016
- PDM N/A
- Fundamental
- Price
- NTLA $9.02
- PDM $8.70
- Analyst Decision
- NTLA Buy
- PDM Buy
- Analyst Count
- NTLA 22
- PDM 4
- Target Price
- NTLA $19.83
- PDM $9.25
- AVG Volume (30 Days)
- NTLA 8.3M
- PDM 752.6K
- Earning Date
- NTLA 11-06-2025
- PDM 10-27-2025
- Dividend Yield
- NTLA N/A
- PDM 1.43%
- EPS Growth
- NTLA N/A
- PDM N/A
- EPS
- NTLA N/A
- PDM N/A
- Revenue
- NTLA $57,528,000.00
- PDM $565,372,000.00
- Revenue This Year
- NTLA $8.51
- PDM N/A
- Revenue Next Year
- NTLA N/A
- PDM N/A
- P/E Ratio
- NTLA N/A
- PDM N/A
- Revenue Growth
- NTLA 33.52
- PDM N/A
- 52 Week Low
- NTLA $5.90
- PDM $5.46
- 52 Week High
- NTLA $28.25
- PDM $10.02
- Technical
- Relative Strength Index (RSI)
- NTLA 35.68
- PDM 62.61
- Support Level
- NTLA $8.96
- PDM $7.88
- Resistance Level
- NTLA $8.88
- PDM $8.87
- Average True Range (ATR)
- NTLA 0.63
- PDM 0.27
- MACD
- NTLA 0.26
- PDM 0.07
- Stochastic Oscillator
- NTLA 38.33
- PDM 82.83
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.